BiotechTube

Dolutegravir + Rlipivirine + GSK1265744

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infections, Human Immunodeficiency Virus and Hepatitis

Conditions

Infections, Human Immunodeficiency Virus and Hepatitis

Trial Timeline

Nov 1, 2011 → Feb 1, 2012

NCT ID
NCT01467531

About Dolutegravir + Rlipivirine + GSK1265744

Dolutegravir + Rlipivirine + GSK1265744 is a phase 1 stage product being developed by Shionogi for Infections, Human Immunodeficiency Virus and Hepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01467531. Target conditions include Infections, Human Immunodeficiency Virus and Hepatitis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01467531Phase 1Completed

Competing Products

20 competing products in Infections, Human Immunodeficiency Virus and Hepatitis

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
25
VN-0200 + PlaceboDaiichi SankyoPhase 1
33
VN-0200Daiichi SankyoPhase 2
52
MicafunginAstellas PharmaPre-clinical
23
amphotericin B liposomal (Ambisome)Astellas PharmaApproved
85
Parenteral micafungin application + Other parenteral antifungal drugsAstellas PharmaPre-clinical
23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to EverolimusAstellas PharmaApproved
85
MicafunginAstellas PharmaPre-clinical
23
MicafunginAstellas PharmaPhase 1
33
Micafungin + PlaceboAstellas PharmaPhase 3
77
Cefiderocol + Standard of CareShionogiPhase 2
52
Xeruborbactam Oral Prodrug + CeftibutenShionogiPhase 1
33
Cefiderocol + Standard of CareShionogiPhase 2
52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice dailyShionogiPhase 3
77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten PlaceboShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
GW810781ShionogiPhase 2
52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
CefiderocolShionogiPhase 2
52
GSK1349572 + EfavirenzShionogiPhase 1
33

Other Products from Shionogi

Naldemedine + PlaceboApproved
85
Rosuvastatin + HMG CoA inhibitorApproved
85
StatinApproved
85
CefiderocolApproved
85
Duloxetine + Pregabalin + PlaceboApproved
85